Auro Laboratories Share Price

Auro Laboratories Limited, with its corporate operations in Mumbai, functions as an active pharmaceutical ingredient (API) and generic formulation manufacturing company in India. The company was incorporated in 1989 and is a small-cap pharmaceutical company. Auro Laboratories manufactures and sells pharmaceutical products including active pharmaceutical ingredients (APIs), intermediates, and generic formulations for domestic and international markets. The company’s API product range includes antihistamine, muscle relaxant, diuretic, anti-diabetic (including Metformin HCL and Glibenclamide), anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, anti-inflammatory, and specialty chemicals. The company’s manufacturing facility is located at Palghar in Maharashtra and is WHO-GMP and EUGMP certified. 

Auro Laboratories share price on NSE and BSE signifies how market participants react to the company’s operational performance and the overall developments in the generic pharmaceutical sector. The company’s financial health depends on API production volumes, raw material costs including chemical intermediates, capacity utilization rates, export demand, and the performance of its anti-diabetic API and generic formulation segments. Auro Laboratories stock price is influenced by various factors such as earnings, regulatory changes from the Central Drugs Standard Control Organization, drug price controls, and global demand for Metformin and other generic APIs. In the longer run, strategies such as expansion into higher-value APIs, product portfolio diversification, and value-added product development affect the stock market sentiments. All these factors need to be monitored closely to have an idea about the company’s stock price movements. 

Auro Laboratories live share price provides real-time information about the last price traded, bid and ask prices, and volume traded. These indicators represent market activity and liquidity, reflecting investor response to corporate announcements, economic conditions, and sector news. Constant monitoring of the Auro Laboratories live price helps in observing short term price volatility and shows how a stock moves relative to the broader pharmaceutical index. Furthermore, monitoring Auro Laboratories stock price movements helps investors understand real-time market sentiment, price fluctuations, and trading behaviour. It allows them to evaluate short-term performance, and respond to news, quarterly results, or sector trends that may influence the company’s valuation and overall investment outlook. 

Auro Laboratories Limited Company Fundamentals 

A. Company Background

Auro Laboratories Limited was incorporated in 1989 and is engaged in the manufacturing and selling of active pharmaceutical ingredients (APIs), intermediates, and generic formulations in India and internationally. The company operates primarily in the pharmaceutical manufacturing segment, supplying products such as Metformin Hydrochloride, Glibenclamide, and a range of other APIs including antihistamine, muscle relaxant, diuretic, iron deficiency, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, anti-inflammatory, and specialty chemicals. Its manufacturing operations are based in India, with a WHO-GMP and EUGMP certified manufacturing facility located at Palghar in Maharashtra, while corporate functions are managed from its administrative offices in Mumbai, Maharashtra. The company was founded in 1992 and is headquartered in Mumbai. Over time, the company has expanded its production capacity and product portfolio to serve both domestic and export markets, with exports to Southeast Asia, the Middle East, and several European countries. Financial performance is assessed through standard metrics such as revenue growth, operating margins, and capacity utilisation. Market valuation indicators such as the P/E ratio are used by analysts for comparative assessment within the pharmaceutical manufacturing sector. Overall fundamentals are influenced by raw material availability, demand cycles in chronic and acute therapy segments, regulatory approvals, and API price fluctuations. 

B. Company Product Lines

• Metformin Hydrochloride API (first-line treatment for type 2 diabetes) 

• Glibenclamide API 

• Antihistamine APIs 

• Muscle Relaxant APIs 

• Diuretic APIs 

• Iron Deficiency APIs 

• Anti-fungal APIs 

• Anti-ulcer APIs 

• Iodine Supplement APIs 

• Anti-malaria APIs 

• Analgesics APIs 

• Antacids APIs 

• Anti-inflammatory APIs 

• Specialty Chemicals 

• Microcrystalline Cellulose 

C. Company Revenue Model

• Domestic API Sales: Revenue generated through sales of APIs, intermediates, and generic formulations to pharmaceutical companies, drug manufacturers, and institutional buyers across India. 

• Export Sales: Contribution from international customers in Southeast Asia, the Middle East, and several European countries for APIs and intermediates. 

• Contract Manufacturing Income: Revenue from custom manufacturing of pharmaceutical ingredients for third-party companies. 

• Generic Formulation Sales: Income from sale of finished pharmaceutical formulations. 

Revenue performance is primarily influenced by demand for generic drugs, API price fluctuations, regulatory approvals, and competition from other API manufacturers. 

D. Geographic Presence

• Corporate and Registered Office: Administrative and management functions based in Mumbai, Maharashtra. 

• Manufacturing Facility: Production plant located at Palghar, Maharashtra, for manufacturing APIs and intermediates. 

• Distribution Network: Domestic distribution across India through pharmaceutical supply channels. 

• Export Markets: Products supplied to Southeast Asia, the Middle East, and several European countries. 

E. Key Milestones

• 1989: Incorporation of Auro Laboratories Limited. 

• 1992: Commencement of API manufacturing activities. 

• 2005: Manufacturing facility received EUGMP and WHO-GMP certification. 

• 2025: Capacity expansion of Metformin HCL from 1800 MTA to 3600 MTA. 

• Recent years: Continued focus on capacity expansion and new API development. 

F. Industry Perspective

The pharmaceutical API manufacturing industry is capital-intensive and closely linked to demand for generic drugs, regulatory approvals, and healthcare spending. Demand trends are influenced by disease prevalence, generic drug adoption, and insurance penetration. The industry faces fluctuations in raw material (chemical intermediate) prices, regulatory approvals from CDSCO and international agencies, and competitive pricing from global API manufacturers. Drug price control mechanisms and environmental regulations increasingly shape production practices. Companies in this sector must manage regulatory compliance, supply chain logistics, and competition while maintaining efficient manufacturing processes. These factors collectively influence financial performance and investor perception of firms like Auro Laboratories. 

Auro Laboratories Limited Stock Market Presence: Listings and Index Representation 

Auro Laboratories Limited is listed on the National Stock Exchange under the symbol AUROLAB and on the Bombay Stock Exchange with the scrip code 530233. Auro Laboratories share price is actively traded on both exchanges. The company’s market presence is within the small-cap segment of the market. Due to its size and sector focus, Auro Laboratories stock price is generally tracked by investors interested in the API and generic pharmaceutical industry. 

Auro Laboratories Limited is part of several broad-based and sector-specific stock market indices, reflecting its position as a small-cap pharmaceutical company in India. While it is not included in benchmark indices like the Sensex or Nifty 50, it is a constituent of wider market indices such as the BSE SmallCap index. Auro Laboratories share price finds representation in these indices based on its market standing. This presence helps investors track the stock relative to other API and pharmaceutical manufacturing companies. 

Auro Laboratories Limited Stock Performance and Share Price History 

Auro Laboratories share price on the stock exchanges reflects its position as an API and generic formulation manufacturer in India. Its performance is qualitatively driven by factors such as production capacity utilization, management of raw material costs including chemical intermediates, growth in export sales, and the ability to control operational expenses. Investors compare Auro Laboratories share price current movement with other API and pharmaceutical companies to assess relative strength. 

These underlying factors become visible through real market movements across different time periods. Similar trends appear during earnings-driven price changes. Broader sector strength has also supported the stock at various points. Beyond operational and sector influences, corporate actions, such as the company’s capacity expansion of Metformin HCL from 1800 MTA to 3600 MTA and its focus on new API categories, have significantly affected Auro Laboratories share price movements by shaping future growth expectations. This shows how strategic initiatives may trigger short-term swings, even within a regulatory environment influenced by CDSCO approval cycles and API price competition. 

While short-term movements respond to events and announcements, longer-term valuation trends are better captured by Auro Laboratories share price annual high and low levels, offering context beyond daily or weekly changes. A notable peak indicates stronger API demand and stable chemical prices, whereas a significant low aligns with market corrections or sector volatility. These extremes reflect the impact of drug pricing policies, global API price trends, and earnings visibility, providing a framework for understanding historical performance. 

Auro Laboratories share price behaviour mirrors the trading patterns of a small-cap API company within India’s generic pharmaceutical ecosystem. The company’s diversified API portfolio spanning anti-diabetic, anti-fungal, and other therapeutic categories has shaped its price history. Over the past several years, the stock has experienced periods of sharp gains followed by phases of consolidation, with a 52-week range from a high of approximately ₹300 to a low of around ₹160. The stock has shown higher volatility compared to the overall market. 

The company’s performance has closely tracked India’s generic drug demand and API price cycles. Positive momentum appeared during the post pandemic recovery, driven by increased demand for chronic disease management drugs like Metformin. However, periods of high raw material costs and competitive pressure from large API manufacturers have led to consolidation in the stock price. Profitability improved in recent quarters, with net profit in the quarter ended September 2025 rising 100% to ₹0.72 crore as against ₹0.36 crore during the previous quarter ended September 2024, although revenue jumped 187.68% to ₹9.81Cr in the Q2 2025-2026. 

Despite COVID-19 disruptions, Auro Laboratories shares showed resilience during the pandemic recovery phase. While the broader pharmaceutical sector faced supply chain challenges, the company’s established Metformin HCL manufacturing capabilities and WHO-GMP certifications helped the stock recover from pandemic lows. The company maintains a manufacturing facility and has consistently exported its API products to international markets. 

The share price has declined for several recurring reasons. A drop in demand for specific APIs like Metformin directly impacts production volumes and leads to selling pressure. Changes in government policy regarding drug price controls (NPPA) or import duties on chemical intermediates can also cause the stock to fall. Moreover, increases in operational costs (e.g., chemical intermediate procurement or energy expenses) without matching price increases squeeze margins, making the stock less attractive. Periods of global economic slowdown that affect healthcare spending in export markets raise concerns about API volumes, leading to price declines. The stock is sensitive to regulatory news; if the CDSCO issues warnings or import alerts, it can cause Auro Laboratories share price to fall as investors adjust expectations for future growth. Broader market selloffs in small-cap pharmaceutical stocks also pull Auro Laboratories share price lower, regardless of the company’s individual performance. 

Auro Laboratories Limited Investor Relevance and Role in Portfolio 

Auro Laboratories Limited is a holding in small-cap and pharmaceutical sector portfolios, offering exposure to API manufacturing (specifically Metformin HCL), intermediates, and generic formulations. Its inclusion in pharmaceutical indices underscores its importance in India’s generic drug API manufacturing space. The company’s position as a manufacturer of Metformin HCL (a first-line treatment for type 2 diabetes), together with its WHO-GMP and EUGMP certifications and expanding API portfolio, makes it a consideration for long-term allocations. 

Auro Laboratories share price is influenced by the company’s ownership structure. Auro Laboratories’ equity is held by a broad mix of promoters, institutional investors, and retail investors, reflecting its standing in India’s pharmaceutical sector. Promoters hold a stable majority stake of approximately 52.18%, reflecting strong internal control. Domestic institutional investors hold a negligible share, and foreign institutional investors hold no stake. The public holds the remaining stake of approximately 47.82%. The company’s management includes Executive Chairman & MD Sharat Sahadeolal Deorah and Whole Time Director Siddhartha Sharat Deorah. This investor base, with stable promoter participation, underscores the company’s role as a holding in both domestic and focused portfolios concentrating on pharmaceutical API manufacturing. 

Beyond fundamentals and ownership, Auro Laboratories stock price is actively monitored in cash market segments, where trading volumes and delivery patterns reflect expectations on API prices, regulatory approvals, and policy actions affecting drug pricing. The stock is available for trading on both major Indian exchanges, allowing investors to take positions based on their outlook for the pharmaceutical sector. Market participants watch these trading indicators to gauge sentiment around quarterly results and policy announcements, such as changes in drug price control orders. 

Technical indicators provide additional insight into short-term momentum shifts in Auro Laboratories share price. While these indicators are primarily used for near-term trading decisions, they also help investors and portfolio managers understand broader market sentiment and anticipate potential volatility, especially around key events or announcements. In the short term and weekly timeframe, the stock has exhibited price movements that correlate with broader pharmaceutical sector trends. Based on available data, Auro Laboratories share price beta indicates moderate volatility compared to the broader market. The company’s debt to equity ratio reflects a low to moderate use of leverage. Return on equity and return on capital employed are at modest levels, and the company’s book value per share serves as a reference point for valuation. 

Overall, Auro Laboratories stock price demonstrates moderate volatility depending on the measurement period, with the stock generally considered to have sensitivity to sector-specific factors such as API price fluctuations, regulatory approvals, and competition in the Metformin API market. 

Auro Laboratories Limited Sectoral Relevance and Peer Positioning 

Auro Laboratories Limited sector relevance stems from its three-decade presence in the API manufacturing industry, its position as a manufacturer of Metformin Hydrochloride (a first-line treatment for type 2 diabetes) and other APIs including antihistamine, muscle relaxant, diuretic, anti-fungal, anti-ulcer, iodine supplement, anti-malaria, analgesics, antacids, anti-inflammatory, and specialty chemicals, its WHO-GMP and EUGMP certified manufacturing facility located at Palghar, Maharashtra, its recent capacity expansion from 1800 MTA to 3600 MTA, its export presence across Southeast Asia, the Middle East, and several European countries, and its role as a supplier to generic drug manufacturers, establishing it as a focused small-cap API provider supporting India’s pharmaceutical manufacturing ecosystem. Peer comparisons with API manufacturing companies like Granules India, Aurobindo Pharma, Divi’s Laboratories, Laurus Labs, and other small-cap API manufacturers focus on production capacity, product mix, export presence, and value-added product diversification rather than short-term stock moves. These benchmarks help investors assess operational scale, efficiency, and regulatory adherence. Institutional tracking of API prices, drug price controls, and CDSCO approvals further highlights Auro Laboratories positioning within India’s broader API manufacturing market. 

Auro Laboratories P/E ratio reflects how investors perceive the company’s earnings relative to its revenue streams from Metformin HCL and other APIs. Based on available data, the current P/E ratio has shown variation with earnings cycles. The company’s profit after tax improved in recent periods, with net profit in the quarter ended September 2025 rising 100.00% to ₹0.72 crore as against ₹0.36 crore during the previous quarter ended September 2024. Quarterly performance has shown sequential improvement, with revenue jumping 187.68% to ₹9.81Cr in the Q2 2025-2026. The company’s earnings before interest and taxes for a recent quarter stood at a certain level, with a corresponding EBIT margin. The net profit margin improved in a recent quarter compared to the same quarter of the prior year. Overall, these changes highlight how market sentiment evolved alongside the company’s operational performance in a cyclical API industry. 

Alongside valuation, Auro Laboratories earnings per share provide insight into its operational performance and income generation from API sales. Based on available data, the company reported a basic EPS in a recent quarter that was higher than the previous quarter and higher than the same quarter of the prior year, showing notable improvement. The trailing twelve-month EPS stands at a moderate level. The company’s EPS for the last full fiscal year was lower compared to the prior fiscal year. The company has a face value per share of ₹10. More recent quarterly performance suggests that EPS has shown strong sequential growth as the company benefited from cost optimization and improved product mix. 

Auro Laboratories market cap highlights its position as a small-cap player within India’s API manufacturing sector. Based on recent data, the company’s market capitalization has moved in line with investor perceptions of the company’s growth potential following a significant correction from its highs. From earlier years through more recent periods, the market cap showed an increasing trend as the company expanded its capacity and diversified into new APIs, followed by a significant correction. This pattern reflects strong investor confidence during favourable pharmaceutical cycles, followed by contraction during challenging periods impacted by cheap API imports and rising raw material costs. This decrease mirrors the correction in Auro Laboratories share price from its annual high to recent levels. 

Finally, Auro Laboratories earnings trajectory demonstrates the impact of its operational execution in a competitive API industry. In recent fiscal years, total income showed trends supported by the core Metformin HCL business. Based on available data, the company’s revenue from operations increased in the most recent quarter compared to the same quarter of the prior year. Total income increased over the same period. Profit after tax improved significantly. However, quarterly performance has shown variability across different quarters. The company has faced headwinds from fluctuating chemical intermediate prices, cheap API imports, and increased competitive pressures from larger API manufacturers. However, the company has expanded into new API categories over the last couple of years, including anti-fungal and anti-ulcer APIs, and expects a certain level of sales revenue in the coming times. These developments illustrate the cyclical nature of the API manufacturing industry and the company’s position within this sector. 

Over time, Auro Laboratories market cap has moved in relation to API sector peers. The company’s earnings have followed the pattern typical of API manufacturing businesses, with revenue performance connecting directly to bulk drug demand and raw material cycles. Quarterly earnings have shown variability influenced by raw material costs and export order flow. The earnings per share figure has followed the trajectory of overall profitability. The price-to-earnings multiple has varied over time, reflecting changing investor expectations about demand for Metformin HCL and other APIs. When generic drug demand picks up and chemical costs stabilize, the multiple may expand. Conversely, during periods of weak demand or rising raw material costs, the multiple may contract. Comparisons with peer API manufacturing companies help investors understand relative valuation. 

Summary 

Auro Laboratories Limited operates as a small-cap API manufacturing company with a three-decade operating history, specialising in Metformin HCL and other generic APIs for the pharmaceutical industry. Auro Laboratories share price reflects investor assessment of generic drug demand, API price cycles, and regulatory approvals. The stock trades on both NSE and BSE within the small-cap segment. Operational performance depends on API demand and raw material costs, while Auro Laboratories stock price movements are observed by market participants tracking the API and generic pharmaceutical sector.